MBCProject_1334_T1_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- WNT_BETA_CATENIN_SIGNALING+0.220
- HEDGEHOG_SIGNALING+0.170
- MITOTIC_SPINDLE+0.160
- ALLOGRAFT_REJECTION+0.110
- E2F_TARGETS+0.110
- G2M_CHECKPOINT+0.110
- ANGIOGENESIS+0.090
- MYC_TARGETS_V1+0.090
Top 10 suppressed
- ADIPOGENESIS-0.450
- FATTY_ACID_METABOLISM-0.420
- OXIDATIVE_PHOSPHORYLATION-0.410
- CHOLESTEROL_HOMEOSTASIS-0.360
- HEME_METABOLISM-0.360
- TNFA_SIGNALING_VIA_NFKB-0.360
- PROTEIN_SECRETION-0.310
- PEROXISOME-0.300
- XENOBIOTIC_METABOLISM-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1001 | — | — | 0.802 |
| 2 | 73f8f4d0-1a2a-44ae-9e99-be730660d7c7 | — | — | 0.802 |
| 3 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.795 |
| 4 | SRR8518135 | — | D | 0.793 |
| 5 | SRR4296090 | — | cohortMD1 | 0.785 |
| 6 | 7107da6d-83c9-47af-bbf5-c677e50dcfad | — | — | 0.772 |
| 7 | BS_VPBMDMQX | medulloblastoma | — | 0.770 |
| 8 | a9e8922f-fd6c-412d-85f5-40f5ea9b5455 | — | — | 0.770 |
| 9 | MNG459 | — | — | 0.768 |
| 10 | TCGA-CR-7398-01A-11R-2016-07 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.110 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.110 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |